Literature DB >> 22244889

CRKL plays a pivotal role in tumorigenesis of head and neck squamous cell carcinoma through the regulation of cell adhesion.

Hiroko Yanagi1, Lei Wang, Hiroshi Nishihara, Taichi Kimura, Mishie Tanino, Teruki Yanagi, Satoshi Fukuda, Shinya Tanaka.   

Abstract

The signaling adapter protein CRK is an indispensable molecule involved in regulating the malignant potential of human cancers. CRK-like (CRKL) is a hematopoietic cell-dominant homologue of CRK that is reported to be phosphorylated by BCR-ABL tyrosine kinase in chronic myelogenous leukemia patients, but its biological function in non-hematopoietic tumors remains unclear. In this study, we explored the tumorigenic role of CRKL in head and neck squamous cell carcinoma (HNSCC) in vitro and in vivo. Immunoprecipitation analysis of HNSCC cell line, HSC-3 cells, showed that the dominant binding partner for C3G was CRKL, not CRK. To clarify the molecular function of CRKL, we established lentiviral shRNA-mediated CRKL-knockdown HNSCC cell lines. In CRKL-knockdown HSC-3 and HSC-4 cells, cell growth and motility were diminished compared to control cells. Cell adhesion assays showed that cell attachment onto both fibronectin- and collagen-coated dishes was significantly suppressed in CRKL-knockdown HSC-3 cells, while no significant change was observed for poly-l-lysine-coated dishes. Immunofluorescence staining revealed that focal adhesion was reduced in CRKL-knockdown HSC-3 cells. With a pulldown assay, CRKL-knockdown HSC-3 cells showed decreased amounts of active Rap1 compared to control cells. Moreover, in an in vivo assay, tumor formation of CRKL-knockdown HSC-3 cells in nude mice was significantly abrogated. Our results indicate that CRKL regulates HNSCC-cell growth, motility, and integrin-dependent cell adhesion, suggesting that CRKL plays a principal role in HNSCC tumorigenicity.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22244889     DOI: 10.1016/j.bbrc.2011.12.142

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  The association of Crk-like adapter protein with poor prognosis in glioma patients.

Authors:  Chengjun Yao; Shunzeng Lv; Mingzhi Han; Jie Zhang; Ya Zhang; Li Zhang; Ruiyang Yi; Dongxiao Zhuang; Jinsong Wu
Journal:  Tumour Biol       Date:  2014-02-22

2.  Fibroblast Growth Requires CT10 Regulator of Kinase (Crk) and Crk-like (CrkL).

Authors:  Taeju Park; Mateusz Koptyra; Tom Curran
Journal:  J Biol Chem       Date:  2016-11-02       Impact factor: 5.157

3.  Models of crk adaptor proteins in cancer.

Authors:  Emily S Bell; Morag Park
Journal:  Genes Cancer       Date:  2012-05

4.  The clinical implications of Crk-like adaptor protein expression in papillary thyroid microcarcinoma.

Authors:  Xiangshan Yang; Wenyuan Lv; Ranran Shi; Shaomei Cheng; Jing Zhang; Zhongfa Xu
Journal:  Tumour Biol       Date:  2014-09-04

5.  Circ_0001206 regulates miR-665/CRKL axis to alleviate hypoxia/reoxygenation-induced cardiomyocyte injury in myocardial infarction.

Authors:  Dongmei Wang; Limei Tian; Yan Wang; Xiaoli Gao; Hanbo Tang; Junbo Ge
Journal:  ESC Heart Fail       Date:  2022-01-13

6.  Molecular dynamics of the proline switch and its role in Crk signaling.

Authors:  Junchao Xia; Ronald M Levy
Journal:  J Phys Chem B       Date:  2014-04-16       Impact factor: 2.991

7.  Genomic analysis of head and neck cancer cases from two high incidence regions.

Authors:  Sandra Perdomo; Devasena Anantharaman; Matthieu Foll; Behnoush Abedi-Ardekani; Geoffroy Durand; Luciana Albina Reis Rosa; Reetta Holmila; Florence Le Calvez-Kelm; Eloiza H Tajara; Victor Wünsch-Filho; José Eduardo Levi; Marta Vilensky; Jerry Polesel; Ivana Holcatova; Lorenzo Simonato; Cristina Canova; Pagona Lagiou; James D McKay; Paul Brennan
Journal:  PLoS One       Date:  2018-01-29       Impact factor: 3.240

Review 8.  Crk and CrkL as Therapeutic Targets for Cancer Treatment.

Authors:  Taeju Park
Journal:  Cells       Date:  2021-03-27       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.